220 related articles for article (PubMed ID: 23614566)
61. Inter-individual variability of in vivo CYP2D6 activity in different genotypes.
Chiba K; Kato M; Ito T; Suwa T; Sugiyama Y
Drug Metab Pharmacokinet; 2012; 27(4):405-13. PubMed ID: 22277677
[TBL] [Abstract][Full Text] [Related]
62. Rifampin-Mediated Induction of Tamoxifen Metabolism in a Humanized PXR-CAR-CYP3A4/3A7-CYP2D6 Mouse Model.
Chang JH; Chen J; Liu L; Messick K; Ly J
Drug Metab Dispos; 2016 Nov; 44(11):1736-1741. PubMed ID: 27538915
[TBL] [Abstract][Full Text] [Related]
63. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
[TBL] [Abstract][Full Text] [Related]
64. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.
Li F; Wang L; Guo GL; Ma X
Drug Metab Dispos; 2010 May; 38(5):871-8. PubMed ID: 20103582
[TBL] [Abstract][Full Text] [Related]
65. Farnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner.
Pan X; Lee YK; Jeong H
Drug Metab Dispos; 2015 Jul; 43(7):1002-7. PubMed ID: 25926433
[TBL] [Abstract][Full Text] [Related]
66. Sex steroid hormones differentially regulate CYP2D in female wild-type and CYP2D6-humanized mice.
Konstandi M; Andriopoulou CE; Cheng J; Gonzalez FJ
J Endocrinol; 2020 May; 245(2):301-314. PubMed ID: 32171179
[TBL] [Abstract][Full Text] [Related]
67. Regional distribution of cytochrome P450 2D1 in the rat central nervous system.
Norris PJ; Hardwick JP; Emson PC
J Comp Neurol; 1996 Mar; 366(2):244-58. PubMed ID: 8698885
[TBL] [Abstract][Full Text] [Related]
68. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.
Niwa T; Hiroi T; Tsuzuki D; Yamamoto S; Narimatsu S; Fukuda T; Azuma J; Funae Y
Brain Res Mol Brain Res; 2004 Oct; 129(1-2):117-23. PubMed ID: 15469888
[TBL] [Abstract][Full Text] [Related]
69. The endogenous substrates of brain CYP2D.
Wang X; Li J; Dong G; Yue J
Eur J Pharmacol; 2014 Feb; 724():211-8. PubMed ID: 24374199
[TBL] [Abstract][Full Text] [Related]
70. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
Marcucci KA; Pearce RE; Crespi C; Steimel DT; Leeder JS; Gaedigk A
Drug Metab Dispos; 2002 May; 30(5):595-601. PubMed ID: 11950793
[TBL] [Abstract][Full Text] [Related]
71. Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro.
Wang Z; Wang L; Xu RA; Zhan YY; Huang CK; Dai DP; Cai JP; Hu GX
Drug Des Devel Ther; 2016; 10():1909-16. PubMed ID: 27354764
[TBL] [Abstract][Full Text] [Related]
72. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
[TBL] [Abstract][Full Text] [Related]
73. The catalytic competence of cytochrome P450 in the synthesis of serotonin from 5-methoxytryptamine in the brain: an in vitro study.
Haduch A; Bromek E; Sadakierska-Chudy A; Wójcikowski J; Daniel WA
Pharmacol Res; 2013 Jan; 67(1):53-9. PubMed ID: 23098818
[TBL] [Abstract][Full Text] [Related]
74. Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation.
Rodgers JT; Davydova NY; Paragas EM; Jones JP; Davydov DR
Biochem Pharmacol; 2018 Oct; 156():86-98. PubMed ID: 30114388
[TBL] [Abstract][Full Text] [Related]
75. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
76. Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.
Mann A; Tyndale RF
Eur J Neurosci; 2010 Apr; 31(7):1185-93. PubMed ID: 20345925
[TBL] [Abstract][Full Text] [Related]
77. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism.
Lewis DF; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1997 Apr; 27(4):319-39. PubMed ID: 9149373
[TBL] [Abstract][Full Text] [Related]
78. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
79. Genetic transmission of cytochrome P450 2D6 (CYP2D6) ultrarapid metabolism: implications for breastfeeding women taking codeine.
Madadi P; Ciszkowski C; Gaedigk A; Leeder JS; Teitelbaum R; Chitayat D; Koren G
Curr Drug Saf; 2011 Feb; 6(1):36-9. PubMed ID: 21241245
[TBL] [Abstract][Full Text] [Related]
80. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model.
Hintermann E; Holdener M; Bayer M; Loges S; Pfeilschifter JM; Granier C; Manns MP; Christen U
J Autoimmun; 2011 Nov; 37(3):242-53. PubMed ID: 21795021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
